![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
First-in-Human Trial of MK-8591-Eluting Implants Demonstrates
Concentrations Suitable for
HIV Prophylaxis for at Least
One Year
|
|
|
10th IAS Conference on HIV Science (IAS 2019), July 21-24, 2019, Mexico City
Randolph Matthews, MD, PhD
Sr. Principal Scientist
Translational Pharmacology, Merck & Co., Inc., Kenilworth, NJ, USA
![0724191](../images/072519/072519-13/0724191.gif)
![0724192](../images/072519/072519-13/0724192.gif)
![0724193](../images/072519/072519-13/0724193.gif)
![0724194](../images/072519/072519-13/0724194.gif)
![0724195](../images/072519/072519-13/0724195.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|